SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
Recent Articles
- Kodiak Sciences Showcases Versatile Therapeutics for Ocular Conditions
- Bunker Hill Mining Corp Updates RSU Vesting Schedule and Plans
- Aroa Biosurgery Advances in Treating Venous Leg Ulcers
- Korea Electric Power Corporation Unveils Annual Report Insights
- Bankees Foundation and Mastercard Unite for Crypto Innovation
- Faruqi & Faruqi Investigates Claims for Investors of Sana
- HistoIndex Attracts Major Investment for Innovative Expansion Journey
- Investors Urged to Explore Legal Options Against Fluence Energy
- Investors of Napco Security Technologies Encouraged to Act Now
- Investors Alert: Legal Investigation into Perpetua Resources
- Exploring the Future of the Polymethyl Methacrylate Market
- UMH Properties Announces First Quarter 2025 Financial Insights
- Investors Urged to Act: Faruqi & Faruqi Investigates TBBK
- Investigation into Everus: What Investors Need to Know Now
- Insights for Solaris Energy Investors on Legal Options Ahead
- Investors Invited to Join TFI International Class Action
- Investors Eye e.l.f. Beauty Amid Legal Investigations
- Investors Stand Strong amid enCore Energy’s Unfolding Issues
- Faruqi & Faruqi Investigates Geron Corporation Securities Claims
- Keurig Dr Pepper Prices Secondary Offering of Shares
- Smart Digital Group Limited Schedules Share Offering
- Investigation into Bakkt Holdings: Understanding the Claims
- First National Bank Alaska Announces Upcoming Cash Dividend
- COFIDE Announces Completion of its Tender Offer for Notes
- Understanding SoundHound AI's Legal Challenges and Investor Rights
- Investors Urged to Take Action on AppLovin Securities Claims
- Fortis Law Partners Announces Key Promotions of Attorneys
- Equinor's Strategic Sale of Peregrino Field: A $3.5 Billion Move
- BTC Digital Ltd. Enhances Operations with New Hosting Agreement
- Investors Urged to Take Action Against BigBear.ai for Losses
- Detroit Amplifiers Welcome Star Coaches for BIG3 Season
- Investors Urged to Connect with Faruqi & Faruqi on Zynex Claims
- Investors May Stand to Gain from NET Power Legal Action
- Opportunity for CGC Investors to Join Securities Class Action
- Understanding Your Rights: Actinium Pharmaceuticals and Investor Losses
- Genmab's Strategic Move Towards FDA Submission for Epcoritamab
- Faircourt Gold Income Corp. Reveals Class A Share Redemption Details
- Brazil Potash Prepares for Key Investor Engagements and Updates
- Final Teams of CIEE UNHCR Challenge Ready to Make Impact
- Investigation into Maravai LifeSciences: Your Rights Explained
- Open Lending Corporation Faces Class Action Investors Alert
- HASA Expands Horizons with Acquisition of Clearwater Chemicals
- Investors Alert: Faruqi & Faruqi Reviews Claims on Ready Capital
- FioBit: Innovating the Future of Cloud Mining for Everyone
- Critical Investor Alert: Skyworks Solutions Needs Attention
- Teleflex Class Action Investigation: Key Details for Investors
- Investors of Ultra Clean Urged to Act Amidst Stock Decline
- Leadership Transition at Huntsman Corporation Announced
- Celebrating International Jazz Day 2025: A Global Music Fest
- Bully Max Excels at American Advertising Awards with Triple Win